NASDAQ
1.07USD
-0.13 (-10.46%)
We have scored 6 news catalysts on NovaBridge Biosciences (NBP) over the past 12 months. The biggest single-day move next to one of them came Nov 3, 2026, when NBP closed −10.8%: “I-Mab Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDA”. Coverage across the window leans positive (average ticker sentiment +0.72). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
123.3M
P/E
—
EPS
—
Beta
1.60
52W range
1.06-5.19
Day range
1.06–1.20
Open
1.20
Prev close
1.20
Volume
1.1M
Avg volume
485.6K
Dividend
0.00
IPO
2020-01-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about NovaBridge Biosciences — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NBP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
